Biotech Values

[DewDiligence]

EXAS—If they were smart they would figure out some way to cap the out-of-pocket costs—better to make a sale (even at breakeven or a small loss) than lose it altogether.

EXAS’ CEO recently stated that, as a matter of policy, EXAS will not sell Cologuard to any US private-insurance plan for less then the Medicare price, which is approximately $500 (#msg-109559217). This statement came before the USPSTF surprise, however, so the Cologuard pricing policy may be under review.

EXAS will sell Cologuard to self-pay patients for $50 up-front and bill them for the balance if (private) reimbursement is not obtained. Most such patients don't pay the residual amount.